Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

This systematic review and network meta-analysis found that spinal cord stimulation therapies for treatment of chronic pain in back and/or lower extremities were associated with greater improvements ...

US-based device company Nevro has secured market authorisation from the European Union (EU) for its HFX iQ spinal cord ...

Transcutaneous Spinal Cord Stimulation Enables Recovery of Walking in Children with Acute Flaccid Myelitis Go to source) shows that a combination of Transcutaneous Spinal Cord Stimulation (TSS ...

The global spinal cord stimulators market is on a robust growth trajectory, poised to reach an impressive valuation of USD 5,441.4 million by 2033. Currently valued at USD 2,702.7 million in 2023, the ...

Nevro's HFX iQ spinal cord stimulator earned the European Union's CE mark, the company said Nov. 12.

Patients used a Senza, Senza II, or Omnia device offering 10 kHz Therapy ... non-pharmacologic innovation that has impacted ...

Spinal cord stimulation at 10 kHz yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with painful diabetic neuropathy and type 2 diabetes. High-frequency spinal cord ...

Kessler Foundation researchers published new findings on neuromodulation in individuals with high-level spinal cord injury ...

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.